Abstract
It was recently reported that the human CD109 gene encodes a glycosyl-phosphatidylinositol-anchored glycoprotein that is a member of the α2-macroglobulin/C3, C4, C5 family of thioester-containing proteins. In this study, we found that the expression of mouse CD109 gene was upregulated in NIH3T3 cells expressing RET tyrosine kinase with a multiple endocrine neoplasia 2B mutation. Northern blot analysis showed a high level of expression of the CD109 gene only in the testis in normal human and mouse tissues. In addition, its expression was high in some human tumor cell lines, which included squamous cell carcinoma and glioblastoma cell lines, whereas it was undetectable in neuroblastoma and small-cell lung carcinoma cell lines. When CD109 expression was examined in 33 cases of human lung cell carcinomas by quantitative RT–PCR, a significant high expression of CD109 was detected in about half of squamous cell carcinomas examined, but not in adenocarcinoma, large-cell carcinoma and small-cell carcinoma. Similarly, upregulation of CD109 was observed in nine out of 17 esophageal squamous cell carcinomas. Thus, these results suggested that CD109 might be a useful molecular target for the development of new therapeutics for malignant tumors, such as squamous cell carcinoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Haregewoin A, Solomon K, Hom RC, Soman G, Bergelson JM, Bhan AK and Finberg RW . (1994). Cell. Immunol., 156, 357–370.
Hofmann K, Bucher P, Falquet L and Bairoch A . (1999). Nucleic Acids Res., 27, 215–219.
Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, Nayar R, Wu X-F and Schuh AC . (2002). Blood, 99, 1683–1691.
Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, Yeo EL, Schuh AC and Sutherland DR . (1999). Exp. Hematol., 27, 1282–1294.
Rappold I, Ziegler BL, Kohler I, Marchetto S, Rosnet O, Birnbaum D, Simmons PJ, Zannettino AC, Hill B, Neu S, Knapp W, Alitalo R, Alitalo K, Ullrich A, Kanz L and Buhring HJ . (1997). Blood, 90, 111–125.
Smith JW, Hayward CP, Horsewood P, Warkentin TE, Denomme GA and Kelton JG . (1995). Blood, 86, 2807–2814.
Solomon KR, Mallory MA and Finberg RW . (1998). Biochem. J., 334, 325–333.
Sutherland DR and Yeo E . (1995). CDw109 Cluster Report: Leukocyte Typing V, Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF and Todd RF (eds). Oxford University Press: Oxford, pp. 1767–1769.
Sutherland DR and Yeo E . (1998). CD109 Workshop Panel Report: Leukocyte Typing VI, Kishimoto T, Kikutani H, von dem Borne AEGKr., Goyert SM, Mason DY, Miyasaka M, Moretta L, Okumura K, Shaw S, Springer TA, Sugamura K, Zola H (eds). Garland Publishing: London, pp. 714–716.
Sutherland DR, Yeo E, Ryan A, Mills GB, Bailey D and Baker MA . (1991). Blood, 77, 84–93.
Takahashi M . (2001). Cytokine Growth Factor Rev., 12, 361–373.
Watanabe T, Ichihara M, Hashimoto M, Shimono K, Shimoyama Y, Nagasaka T, Murakumo Y, Murakami H, Sugiura H, Iwata H, Ishiguro N and Takahashi M . (2002). Am. J. Pathol., 161, 249–256.
Yeo EL and Sutherland DR . (1992). Blood, 80, 56.
Acknowledgements
This work was supported in part by Grants-in-Aid for COE (Center of Excellence) Research, Scientific Research and Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. We thank K Imaizumi and K Uchiyama for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hashimoto, M., Ichihara, M., Watanabe, T. et al. Expression of CD109 in human cancer. Oncogene 23, 3716–3720 (2004). https://doi.org/10.1038/sj.onc.1207418
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207418
Keywords
This article is cited by
-
CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer
Virchows Archiv (2022)
-
Potential biomarkers of childhood brain tumor identified by proteomics of cerebrospinal fluid from extraventricular drainage (EVD)
Scientific Reports (2021)
-
CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma
British Journal of Cancer (2020)
-
CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro
Scientific Reports (2019)
-
CD109 and squamous cell carcinoma
Journal of Translational Medicine (2018)